Search research articles
Contact Us
Filters
Showing results (101-110 of 132) with videos related to
Page
of 14
Sort By:
The Lancet. Oncology
|
December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Journal for Immunotherapy of Cancer
|
July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
Xiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Transplantation and Cellular Therapy
|
September 21, 2024
Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy
Aasha I Hoogland, Anna Barata, Xiaoyin Li, et al.
Blood Advances
|
December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
Michael D Jain, Miriam T Jacobs, Feng Gao, et al.
Blood Advances
|
August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Narendranath Epperla, Ying Huang, Amanda F Cashen, et al.
Journal of the American College of Cardiology
|
December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Julio C Chavez, Francine M Foss, Basem M William, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Miriam T Jacobs, Michael D Jain, Feng Gao, et al.
Cancer
|
July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy
Narendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
American Journal of Hematology
|
November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies
Luciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 132) with videos related to
Sort By:
Page
of 14
The Lancet. Oncology
|
December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Journal for Immunotherapy of Cancer
|
July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
Xiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Transplantation and Cellular Therapy
|
September 21, 2024
Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy
Aasha I Hoogland, Anna Barata, Xiaoyin Li, et al.
Blood Advances
|
December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
Michael D Jain, Miriam T Jacobs, Feng Gao, et al.
Blood Advances
|
August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Narendranath Epperla, Ying Huang, Amanda F Cashen, et al.
Journal of the American College of Cardiology
|
December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Julio C Chavez, Francine M Foss, Basem M William, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Miriam T Jacobs, Michael D Jain, Feng Gao, et al.
Cancer
|
July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy
Narendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.
American Journal of Hematology
|
November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies
Luciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
Page
of 14